115 related articles for article (PubMed ID: 23332368)
21. Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands.
Spadoni G; Bedini A; Guidi T; Tarzia G; Lucini V; Pannacci M; Fraschini F
ChemMedChem; 2006 Oct; 1(10):1099-105. PubMed ID: 16955531
[TBL] [Abstract][Full Text] [Related]
22. Homology models of melatonin receptors: challenges and recent advances.
Pala D; Lodola A; Bedini A; Spadoni G; Rivara S
Int J Mol Sci; 2013 Apr; 14(4):8093-121. PubMed ID: 23584026
[TBL] [Abstract][Full Text] [Related]
23. 7-Substituted-melatonin and 7-substituted-1-methylmelatonin analogues: effect of substituents on potency and binding affinity.
Faust R; Garratt PJ; Trujillo Pérez MA; Piccio VJ; Madsen C; Stenstrøm A; Frølund B; Davidson K; Teh MT; Sugden D
Bioorg Med Chem; 2007 Jul; 15(13):4543-51. PubMed ID: 17459711
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
[TBL] [Abstract][Full Text] [Related]
25. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
Ayoub MA; Levoye A; Delagrange P; Jockers R
Mol Pharmacol; 2004 Aug; 66(2):312-21. PubMed ID: 15266022
[TBL] [Abstract][Full Text] [Related]
26. Application of the bridgehead fragments for the design of conformationally restricted melatonin analogues.
Zefirova ON; Baranova TY; Ivanova AA; Ivanov AA; Zefirov NS
Bioorg Chem; 2011 Apr; 39(2):67-72. PubMed ID: 21419469
[TBL] [Abstract][Full Text] [Related]
27. High-throughput screening assay for new ligands at human melatonin receptors.
Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
[TBL] [Abstract][Full Text] [Related]
29. Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria.
Elisi GM; Bedini A; Scalvini L; Carmi C; Bartolucci S; Lucini V; Scaglione F; Mor M; Rivara S; Spadoni G
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899888
[No Abstract] [Full Text] [Related]
30. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
Durieux S; Chanu A; Bochu C; Audinot V; Coumailleau S; Boutin JA; Delagrange P; Caignard DH; Bennejean C; Renard P; Lesieur D; Berthelot P; Yous S
Bioorg Med Chem; 2009 Apr; 17(8):2963-74. PubMed ID: 19329323
[TBL] [Abstract][Full Text] [Related]
32. Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor.
Chan KH; Hu Y; Ho MK; Wong YH
Curr Med Chem; 2013; 20(2):289-300. PubMed ID: 23131177
[TBL] [Abstract][Full Text] [Related]
33. Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
Larraya C; Guillard J; Renard P; Audinot V; Boutin JA; Delagrange P; Bennejean C; Viaud-Massuard MC
Eur J Med Chem; 2004 Jun; 39(6):515-26. PubMed ID: 15183910
[TBL] [Abstract][Full Text] [Related]
34. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
[TBL] [Abstract][Full Text] [Related]
35. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
36. NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization.
Chegaev K; Lazzarato L; Rolando B; Marini E; Tosco P; Cena C; Fruttero R; Bertolini F; Reist M; Carrupt PA; Lucini V; Fraschini F; Gasco A
J Pineal Res; 2007 Apr; 42(4):371-85. PubMed ID: 17439554
[TBL] [Abstract][Full Text] [Related]
37. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
[TBL] [Abstract][Full Text] [Related]
38. Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II.
Mayadevi M; Sherin DR; Keerthi VS; Rajasekharan KN; Omkumar RV
Bioorg Med Chem; 2012 Oct; 20(20):6040-7. PubMed ID: 22989913
[TBL] [Abstract][Full Text] [Related]
39. Structure and activity relationship of 2-(substituted benzoyl)-hydroxyindoles as novel CaMKII inhibitors.
Komiya M; Asano S; Koike N; Koga E; Igarashi J; Nakatani S; Isobe Y
Bioorg Med Chem Lett; 2011 Mar; 21(5):1456-8. PubMed ID: 21292482
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of cyclic AMP-response element-binding protein (CREB) is influenced by melatonin treatment in pancreatic rat insulinoma β-cells (INS-1).
Bazwinsky-Wutschke I; Wolgast S; Mühlbauer E; Albrecht E; Peschke E
J Pineal Res; 2012 Nov; 53(4):344-57. PubMed ID: 22616931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
